These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

768 related articles for article (PubMed ID: 16337092)

  • 101. Neuron-Astrocyte Interactions in Parkinson's Disease.
    Miyazaki I; Asanuma M
    Cells; 2020 Dec; 9(12):. PubMed ID: 33297340
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Critical period for dopaminergic neuroprotection by hormonal replacement in menopausal rats.
    Rodriguez-Perez AI; Borrajo A; Valenzuela R; Lanciego JL; Labandeira-Garcia JL
    Neurobiol Aging; 2015 Feb; 36(2):1194-208. PubMed ID: 25432430
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Uncovering novel actors in astrocyte-neuron crosstalk in Parkinson's disease: the Wnt/β-catenin signaling cascade as the common final pathway for neuroprotection and self-repair.
    Marchetti B; L'Episcopo F; Morale MC; Tirolo C; Testa N; Caniglia S; Serapide MF; Pluchino S
    Eur J Neurosci; 2013 May; 37(10):1550-63. PubMed ID: 23461676
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration.
    Uversky VN
    Cell Tissue Res; 2004 Oct; 318(1):225-41. PubMed ID: 15258850
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Oxidative stress, age-related neurodegeneration, and the potential for neurotrophic treatment.
    Williams LR
    Cerebrovasc Brain Metab Rev; 1995; 7(1):55-73. PubMed ID: 7742172
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Naphthazarin has a protective effect on the 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine-induced Parkinson's disease model.
    Choi SY; Son TG; Park HR; Jang YJ; Oh SB; Jin B; Lee J
    J Neurosci Res; 2012 Sep; 90(9):1842-9. PubMed ID: 22513651
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Gender-specific brain regional variation of neurons, endogenous estrogen, neuroinflammation and glial cells during rotenone-induced mouse model of Parkinson's disease.
    Mitra S; Chakrabarti N; Dutta SS; Ray S; Bhattacharya P; Sinha P; Bhattacharyya A
    Neuroscience; 2015 Apr; 292():46-70. PubMed ID: 25592425
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Nrf2/Wnt resilience orchestrates rejuvenation of glia-neuron dialogue in Parkinson's disease.
    Marchetti B
    Redox Biol; 2020 Sep; 36():101664. PubMed ID: 32863224
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Inflammation and Parkinson's disease pathogenesis.
    Przedborski S
    Mov Disord; 2010; 25 Suppl 1():S55-7. PubMed ID: 20187228
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Sex differences in Parkinson's disease and other movement disorders.
    Smith KM; Dahodwala N
    Exp Neurol; 2014 Sep; 259():44-56. PubMed ID: 24681088
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Influence of estrogens on neurodegenerative processes.
    Członkowska A; Ciesielska A; Joniec I
    Med Sci Monit; 2003 Oct; 9(10):RA247-56. PubMed ID: 14523340
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Estrogen and movement disorders.
    Kompoliti K
    Clin Neuropharmacol; 1999; 22(6):318-26. PubMed ID: 10626091
    [TBL] [Abstract][Full Text] [Related]  

  • 113. [Parkinson's disease: cell death mechanisms].
    Michel PP; Hirsch EC; Agid Y
    Rev Neurol (Paris); 2002; 158(122):24-32. PubMed ID: 12690312
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Deficiency of
    Bai X; Zhang X; Fang R; Wang J; Ma Y; Liu Z; Dong H; Li Q; Ge J; Yu M; Fei J; Sun R; Huang F
    Aging (Albany NY); 2021 Sep; 13(18):22390-22411. PubMed ID: 34543233
    [TBL] [Abstract][Full Text] [Related]  

  • 115. [Caffeine as a preventive drug for Parkinson's disease: epidemiologic evidence and experimental support].
    Góngora-Alfaro JL
    Rev Neurol; 2010 Feb 16-28; 50(4):221-9. PubMed ID: 20198594
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Inflammation and neurodegeneration in Parkinson's disease.
    McGeer PL; McGeer EG
    Parkinsonism Relat Disord; 2004 May; 10 Suppl 1():S3-7. PubMed ID: 15109580
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Sir-2.1 modulates 'calorie-restriction-mediated' prevention of neurodegeneration in Caenorhabditis elegans: implications for Parkinson's disease.
    Jadiya P; Chatterjee M; Sammi SR; Kaur S; Palit G; Nazir A
    Biochem Biophys Res Commun; 2011 Sep; 413(2):306-10. PubMed ID: 21889494
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Menopause and Parkinson's disease. Interaction between estrogens and brain renin-angiotensin system in dopaminergic degeneration.
    Labandeira-Garcia JL; Rodriguez-Perez AI; Valenzuela R; Costa-Besada MA; Guerra MJ
    Front Neuroendocrinol; 2016 Oct; 43():44-59. PubMed ID: 27693730
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Are paradoxical cell cycle activities in neurons and glia related to the metabolic theory of Alzheimer's disease?
    Erol A
    J Alzheimers Dis; 2010; 19(1):129-35. PubMed ID: 20061632
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Inflammation and dopaminergic neuronal loss in Parkinson's disease: a complex matter.
    Hartmann A; Hunot S; Hirsch EC
    Exp Neurol; 2003 Dec; 184(2):561-4. PubMed ID: 14769349
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.